---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-135766"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:58:10.415666+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired

## Summary
- Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.
- R&D expenses $20.5M for FY2025 vs $14.7M in FY2024; operating cash outflow $27.7M.
- Phase 3 trial of IFx-2.0 in Merkel cell carcinoma initiated under FDA SPA; enrollment estimated to complete mid-2027.
- Closed $10.5M acquisition of Kineta, gaining VISTA antibody TBS-2025; $21.2M raised in 2025 offerings.
- Upcoming milestones: FDA meeting for TBS-2025 in June 2026; ADC lead selection in 1H 2026.

## SEC filing metadata
- accession: 0001193125-26-135766
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/hura-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-135766
- JSON: https://secwatch.observer/filing/0001193125-26-135766.json
- Plain text: https://secwatch.observer/filing/0001193125-26-135766.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported financial results for for the Company's fourth quarter and full year ended December 31, 2025.
  - Period: for the Company's fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported financial results for for the year ended December 31, 2025.
  - Period: for the year ended December 31, 2025
  - Result: reported results
  source text: On April 1, 2026, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the year ended December 31, 2025, and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000119312526135766/0001193125-26-135766-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.